Introduction
============

The recent developments in intravenous anesthetics have allowed intravenous anesthetics to move from being complimentary to becoming the main anesthetics during surgery. Propofol and remifentanil\'s context-sensitive half times are short. So, in the setting of total intravenous anesthesia, even when the anesthesia is performed over a long period of time, the recovery time is quite short compared to that of inhalational anesthetics \[[@B1]\]. Remifentanil is an opioid with one of the shortest context-sensitive half times. During endotracheal intubation, it inhibits the activation of the sympathetic nervous system and prevents increases of the blood pressure and heart rate. Much research has been done on the optimal dose for these effects \[[@B2]\]. There are many reports of clinical situations where certain dosage amounts of remifentanil suppressed the hemodynamic and cardiovascular responses from endotracheal intubation in hypertensive patients \[[@B3]\], elderly patients \[[@B4]\] and diabetic patients \[[@B5]\].

Smokers are known to have an extremely increased cardiovascular response compared to that of nonsmokers \[[@B6],[@B7]\]. Yet, there have hardly been any reports on the appropriate dosages of remifentanil for smokers and nonsmokers to repress the cardiovascular response to endotracheal intubation. For smokers, endotracheal intubation increases the myocardial oxygen demand, but it constricts the coronary artery, which elevates vascular resistance and reduces the blood flow rate \[[@B8]\]. So preventing the hemodynamic changes due to endotracheal intubation is very important. We attempted to determine if there is a difference between smokers and nonsmokers for their cardiovascular response to remifentanil that is administered for endotracheal intubation.

Materials and Methods
=====================

Eighty ASA I & II patients of both genders and whose ages were between 30 and 60 and the BMI ranged from 20 to 30 were enrolled in the study. In each gender group, there were 20 smokers and 20 nonsmokers. The gender groups were divided into male smokers (Group MS), male nonsmokers (Group MN), female smokers (Group FS) and female nonsmokers (Group FN), resulting in 4 subgroups. After the approval of the local ethics committee, the authors conducted a preanesthetic visit with the patients. The patients gave us their written informed consent after they were told of the purpose and methodology of the research.

During the preanesthetic visit before surgery, the authors made inquiries about whether or not the patients were smokers. If they had a history of smoking for 2 or more years and they still smoked, then they were placed in the smoking group. The duration of smoking (in months) and the quantity of smoking (number of cigarettes per day) were recorded and we recommended that patients should stop smoking after the preanesthetic visit. If the patient had never smoked, then they were put in the nonsmoking group. Patients were excluded if they had hypertension, diabetes mellitus, neurological disorders or a past history of taking cardiovascular drugs such as beta blockers. Patients were excluded if they were expected to have difficult intubation or if they did not have successful endotracheal intubation on the first try.

As premedication, 30 minutes before the surgery, intramuscular injection was done with ranitidine (Urantac®, Whanin, Korea) 25 mg and midazolam (Dormicum®, Roche, Switzerland) 2.5 mg. The patients were monitored during anesthetic induction with electrocardiography, noninvasive blood pressure measurement and a pulse oxymeter. Lactated Ringer\' solution was administered as intravenous fluid with an 18 G angio needle in a forearm vein. For prehydration, 1/2 of the calculated maintenance volume (2 ml/kg/hr), with considering the NPO time, was infused before induction. Induction of anesthesia was done according to the methodology of Shim et al. \[[@B2]\] as follows. Remifentanil (Ultiva™, GSK, Italy) 1 mg was diluted with 50 ml of normal saline (20 µg/ml), and then using an infusion pump (Pilot C, Fresenius Vial, France), continuous infusion was started at a rating of 10 µg/kg/hr concomitant with administering 6 L/min oxygen with a face mask for 2 minutes. Two minutes after remifentanil infusion, midazolam 0.05 mg/kg and propofol (Provive™, Claris, India) 0.8 mg/kg were administered by intravenous injection to induce unconsciousness. If the patient did not lose consciousness within 1 minute, then propofol 20 mg was additionally administered. The loss of consciousness was checked by the eyelash reflex. Rocuronium (Esmeron®, Organon, Netherlands) 1 mg/kg was intravenously injected over a period of 10 seconds. After controlled ventilation for 2 minutes, endotracheal intubation was performed. Afterwards, the remifentanil infusion was reduced to 2 µg/kg/hr. With the control mode ventilation, anesthesia was maintained with sevoflurane 1.5% in O~2~ : Air = 1.5 L : 2.5 L/min, with a tidal volume of 10 ml/kg and a respiratory rate of 10 bpm.

The measurements of the mean arterial pressure (MAP) and heart rate (HR) were done before anesthetic induction (baseline), at the time of just falling unconsciousness, just before endotracheal intubation, just after intubation and 1, 2 and 3 minutes after intubation. During anesthetic induction, when the systolic blood pressure fell below 80 mmHg, the administration of remifentanil was stopped.

All the measurements are shown as the mean ± standard deviation. SPSS 17.0 (SPSS, Inc., Chicago, IL) was used for statistical analysis. The height, weight and the dosage of remifentanil and the total amount of infused propofol were compared using the Student t-test. The comparisons of heart rates and the MAP between the groups were done using the independent t-test. The changes over time of the heart rates and MAPs within the groups were compared using repeated measures of ANOVA test. P values \< 0.05 were considered to be significant.

Results
=======

There was no significant difference between the male smokers and nonsmokers and between female smokers and nonsmokers for age, weight, height, the administered remifentanil dose and the propofol dose until endotracheal intubation ([Table 1](#T1){ref-type="table"}). None of the patients had their remifentanil infusion stopped because none of the patients had a decreased systolic blood pressure below 80 mmHg during anesthetic induction. There was no difference between the smokers and nonsmokers for the baseline MAPs and heart rates. The average duration of smoking for men was 17.1 years and the average amount smoked was 24 cigarettes per day. For women, the average duration of smoking was 12.7 years. They smoked on average 18 cigarettes per day.

In Group MN, there was no difference between the baseline MAP and the MAP just after endotracheal intubation. In Group MS, the MAP just after endotracheal intubation was significantly increased as compared with the baseline MAP (110.1 ± 17.3 mmHg vs 87.9 ± 4.6 mmHg, respectively) and the MAPs were significantly increased at just after endotracheal intubation (110.1 ± 17.3 mmHg vs 88.8 ± 14.6 mmHg, respectively) and at 1, 2 and 3 minutes after intubation, as compared with Group MN, respectively ([Fig. 1A](#F1){ref-type="fig"}, P \< 0.05). In group MN, the heart rate was significantly increased just after endotracheal intubation (72.5 ± 11.4 bpm vs 64.1 ± 3.5 bpm, respectively) and 1 and 2 minutes after intubation as compared with the baseline heart rate ([Fig. 1B](#F1){ref-type="fig"}, P \< 0.05). In Group MS, the heart rate was significantly increased just after endotracheal intubation (88.5 ± 16.5 bpm vs 68.3 ± 8.74 bpm) and at 1, 2 and 3 minutes after intubation as compared with baseline, respectively, and these values were higher than those of Group MN ([Fig. 1B](#F1){ref-type="fig"}, P \< 0.05).

For women, there was no difference between Group FN and Group FS for the MAP measured just after endotracheal intubation and 1, 2 and 3 minutes after intubation. In Group FN, the MAP was increased just after endotracheal intubation compared to the baseline MAP (98.4 ± 17.3 mmHg vs 86.6 ± 10.0 mmHg, respectively) ([Fig. 2A](#F2){ref-type="fig"}, P \< 0.05). The heart rate in Group FN just after endotracheal intubation was higher than the baseline heart rate (88.6 ± 22.8 bpm vs 77.1 ± 14.8 bpm, respectively). It was significantly increased at 1 and 2 minutes after intubation ([Fig. 2B](#F2){ref-type="fig"}, P \< 0.05). In Group FS, the heart rate just after intubation was increased higher than that of baseline (88.9 ± 10.8 bpm vs 72.4 ± 3.9 bpm, respectively), and it was significantly increased at 1, 2 and 3 minutes after intubation ([Fig. 2B](#F2){ref-type="fig"}, P \< 0.05). But there was no difference in the heart rate between Groups FN and FS ([Fig. 2B](#F2){ref-type="fig"}).

Discussion
==========

Endotracheal intubation is a commonly used, necessary maneuver for securing the airway when inducing general anesthesia. However, endotracheal intubation causes the stimulation of the sympathetic nervous system, which increases the plasma catecholamine level and this can cause an elevated blood pressure and tachycardia \[[@B9]\]. Most myocardial ischemia that occurs during anesthesia is related to endotracheal intubation and especially to tachycardia \[[@B10]\]. So it is important to prevent hemodynamic changes during anesthetic induction.

To minimize such cardiovascular responses, the use of opioids, local anesthetics, inhalational anesthetics, beta adrenergic blockers, calcium channel blockers and other cardiovascular drugs has been shown to be effective \[[@B11]\]. Among them, opioids have been the most widely used drugs. Fentanyl blocks the sympathetic nervous responses during anesthetic induction. The amount of fentanyl used for endotracheal intubation with using a laryngoscope is known to be directly proportional to the ability to suppress the cardiovascular response, so fentanyl has often been used \[[@B12]\], yet remifentanil has recently become more widely used.

There have been many studies on what the appropriate dosage of remifentanil is in order to suppress the hemodynamic response to endotracheal intubation. The methods of administration are a bolus injection, an injection of a loading dose with a continuous infusion, and a continuous infusion. For the induction of anesthesia using propofol and rocuronium, Hall et al. \[[@B13]\] administered a loading dose of remifentanil 0.5 µg/kg and then they continuously infused 0.25 µg/kg/min. Shim et al. \[[@B2]\] reported that continuously infusing remifentanil at 0.2 µg/kg/min effectively suppressed the stimulus-caused increase in blood pressure and heart rate. Their results show that the amount of remifentanil administered until endotracheal intubation was important for inhibiting the hemodynamic response regardless of the method of administration. The optimal dose was normally 1-1.5 µg/kg. This current study followed the methodology of the study by Shim et al. \[[@B2]\] by inducing anesthesia for 6-7 minutes until endotracheal intubation. Thus, we were able to avoid side effects such as muscle rigidity induced by a bolus injection of remifentanil \[[@B14],[@B15]\].

There have been many studies done on the effects of smoking on the cardiovascular system. According to McVeigh et al. \[[@B16]\], the resting heart rate was higher in smokers than in nonsmokers. They also reported that the systolic and diastolic pressures and the MAP were lower in smokers than those in nonsmokers. In a study on only women, Laxton et al. \[[@B6]\] asserted that heart rate of smokers immediately after intubation was significantly greater than that of nonsmokers. Yet Jee and Park \[[@B17]\] argued that the baseline blood pressure and heart rate are not different for smokers and nonsmokers. In fact, in a non-stimulated state, nicotine affects the sympathetic nervous system, it elevates the heart rate and it causes vasoconstriction. Smokers who abstained from smoking for a short period of time experience a reduction in the plasma catecholamine level, which reduces the heart rate and arterial blood pressure \[[@B18]\]. This current study showed no difference in the baseline heart rate or MAP between the smokers and nonsmokers. So our research findings were in accordance with the findings of Jee and Park \[[@B17]\]. But the difference in research findings among the different studies is construed to be due to the different characteristics of the patient subjects such as their age, their history of smoking and their history of abstinence from smoking.

Smoking elevates the blood pressure and the heart rate, but abstinence from smoking during a period of preparation for surgery shows various hemodynamic responses depending on the duration of abstinence and the patients age and gender. Further research needs to be done on this. Moreover, there is no study on the effect of the smoking period on the cardiovascular system, so this needs further research as well.

Smoking has a strong adrenergic agonistic effect, and so it increases the blood pressure, heart rate and systemic vascular resistance \[[@B19]\]. The change in heart rate is controlled by the autonomic nervous system. The effect the autonomic nervous system has on the sinus node is ever-changing due to internal and external factors. The regular change in the heart rate is called heart rate variability. Smoking is said to reduce such heart rate variability \[[@B20]\]. Such reductions are a serious risk factor for cardiac diseases \[[@B21],[@B22]\]. Smokers are two times more as likely to suffer from coronary arterial diseases than are nonsmokers \[[@B23],[@B24]\].

This study showed that there was a difference in the hemodynamic response to endotracheal intubation between male smokers and nonsmokers, while there was not such a difference in the female groups. Jee and Moon \[[@B25]\] reported that men have a longer sustained elevation of systolic blood pressure. It appears that the length of the blood pressure elevation is gender-based, so it is believed that gender also affects the change in hemodynamic responses. Hinojosa-Laborde et al. \[[@B26]\] reported that there is a gender difference in the control of the sympathetic nervous system. The control of the sympathetic nervous system in women is a bit more efficient than that in men. In this study, there was no difference in the endotracheal intubation-caused hemodynamic response in the women groups, regardless of whether they smoked or not. Perhaps this is because the efficient control of the sympathetic nervous system offsets the hemodynamic responses.

In conclusion, for men, there was a difference in the hemodynamic response to endotracheal intubation using remifentanil between the smokers and nonsmokers. However, for women, there was no such difference. There has been much controversy over the gender difference of the endotracheal intubation-caused hemodynamic change. For obtaining consistent results, more research should be performed with controlling for many factors.
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![Changes of the MAP (mean arterial pressure) (A) and HR (heart rate) (B) in the males. The MAP and HR at P0 and 1, 2 and 3 minutes in Group MS were higher than those of Group MN, respectively (P \< 0.05). In Group MS, the HR was increased at P0 and 1, 2 and 3 minutes compared with that at baseline. Group MS: male smokers, Group MN: male nonsmokers, B: baseline, BO: on unconsciousness, BI: just before intubation, P0: just after intubation, P1, 2, 3: 1, 2, 3 minutes after intubation. ^\*^P \< 0.05 compared with baseline, ^†^P \< 0.05 compared with Group MN.](kjae-58-508-g001){#F1}

![Changes of the mean arterial pressure (MAP, A) and heart rate (HR, B) in women. The HRs during postintubation period were increased compared with baseline in each group (P \< 0.05), but there were no differences between the two groups. Group FS: female smokers, Group FN: female nonsmokers, B: baseline, BO: on unconsciousness, BI: just before intubation, P0: just after intubation, P1, 2, 3: 1, 2, 3 minutes after intubation, respectively. ^\*^P \< 0.05 compared with baseline.](kjae-58-508-g002){#F2}
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Values are expressed as means ± SDs. There were no differences in the patient characteristics and baseline values between Group MS and Group MN, and between Group FS and Group FN, respectively. Group MS: male smokers, Group MN: male nonsmokers, Group FS: female smokers, Group FN: female nonsmokers, MAP: mean arterial pressure, HR: heart rate.
